GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Interest Received

Percheron Therapeutics (ASX:PER) Interest Received : A$0.54 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Interest Received?

Percheron Therapeutics's Interest Received for the six months ended in Dec. 2023 was A$0.32 Mil.

Percheron Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.54 Mil.


Percheron Therapeutics Interest Received Historical Data

The historical data trend for Percheron Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Interest Received Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Interest Received
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.03 0.01 0.02 0.36

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.14 0.22 0.32

Percheron Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Percheron Therapeutics Interest Received Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Interest Received provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics (ASX:PER) Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines